Introduction
Paraphenylenediamine is an aromatic amide found in Kala Pathar ("black stone").[1][2] In its pure form, paraphenylenediamine is a white crystal that oxidizes to a brown or dark brown. Although it is mainly manufactured in Japan, Germany, and the United Kingdom, it is more commonly used for its dyeing properties in parts of East Africa, the Middle East, and the Indian subcontinent.[3] Despite typically being used in traditional customs such as henna, it is emerging as a common household poison and suicide agent, particularly in these regions, possibly due to its affordability, ease of accessibility, and high toxicity.[1][2]
However, as with all other intoxicants, the potential for toxicity and its expected presentations can vary based on the route of exposure, amount and concentration of exposure, and the duration of exposure. Reports in the literature primarily focus on the 2 most common routes—transdermal and oral ingestion. Transdermal exposure is typically associated with dermatologic complications of varying severity, whereas oral ingestion—often due to accidental ingestion or suicidal intent—particularly in higher dosages, has been shown to cause severe multiorgan toxicity.[4]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Paraphenylenediamine is commonly used in its powdered form as an additive dyeing agent in various industries, including cosmetics, textiles, and film.[5][6] However, it is more commonly encountered by the general public as a dye in temporary body art called henna, a practice found in many parts of the world. The henna plant Lawsonia inermis is a flowering plant that has been used for centuries for its potent red-orange dyeing properties.[2] This plant is commonly found in Asia, the Middle East, Eastern Africa, and Australia, with its prevalence in customary and cultural practices following a similar distribution.
Henna is typically crushed into a paste and applied to skin, fingernails, and hair to create intricate patterns, often for festive or cultural events.[7] However, paraphenylenediamine has been increasingly added to henna paste to produce black henna. This practice decreases the amount of henna paste required, achieves a darker pigmentation, and speeds up the staining process.[2] Unfortunately, this is an unregulated adulteration of the henna paste in most locations.
In addition to henna body art, paraphenylenediamine is a dark pigmentation in hair dyes. Altering the paraphenylenediamine concentration with an oxidizing agent, such as hydrogen peroxide, can achieve a variety of shades. Shades can range from golden blonde in lower concentrations to jet black in higher concentrations.[3] Studies have shown the safety of paraphenylenediamine hair dye when used topically and in regulated formulations.[8] In developed countries, hair dye formulations have largely become standardized to contain a maximum of 2% paraphenylenediamine in 100 mL solution to decrease toxicity in case of accidental poisoning. Unfortunately, these concentrations may be as high as 90% in underdeveloped and developing countries due to a lack of standardized regulation.[4][5]
A growing trend, particularly in underdeveloped and developing countries, is the consumption of paraphenylenediamine-containing products, such as black henna or hair dye for intentional self-harm purposes. This issue has been documented through multiple case reports and reviews, particularly in Egypt, India, Morocco, Pakistan, Sudan, and Tunisia.[9][10][11][12][13] In the 1990s, paraphenylenediamine toxicity was reported as the leading cause of poisoning in Morocco.[9] This trend is likely due to the general affordability, ease of accessibility, and high potential for toxicity of paraphenylenediamine-containing products.[1][2]
Epidemiology
The worldwide demographic of paraphenylenediamine toxicity shows an average age of 21 to 30 years, with a significant predominance among females.[1][6][14] The most common route of exposure is oral ingestion.[1] Other risk factors include low socioeconomic background, living in rural areas, social and personal conflicts, and the lack of social support.[3]
Data published by the United States Environmental Protection Agency has listed the potential uses and sources of paraphenylenediamine in the United States (US Environmental Protective Agency. P-Phenylenediamine). Despite this, statistical data regarding the incidence of paraphenylenediamine toxicity in the Western world and, in particular, the United States have been limited in the literature.[15]
Furthermore, reporting of paraphenylenediamine toxicity in pediatric populations has also been scarce despite its prevalence, especially in areas where paraphenylenediamine is commonly used. Similar to the adult population, pediatric patients are noted to be predominantly female.[16] The main modality of toxicity in the pediatric population is accidental and suicidal ingestion, with the latter being the primary reason for ingestion in teenage patients.[17][16][18] The importance of considering non-accidental injuries in this vulnerable population should be noted, as cases involving the use of paraphenylenediamine as a homicidal agent have been reported.[17][16] A study found that the mean age of affected pediatric patients was 13.8 years, with ages ranging from 2 to 18 years.[16]
Pathophysiology
The transdermal route exposure to paraphenylenediamine primarily results in dermatologic manifestations, such as varying degrees of acute, subacute, or chronic contact dermatitis, although severe systemic manifestations, such as anaphylaxis, have been reported.[19][20] Delayed type IV hypersensitivity reactions are the most common mechanism; hence, the presentation may have a latent period of hours to days after exposure.[20] The pathophysiology of dermatitis associated with exposure is due to increased activity of multiple enzymes such as beta-glucuronidase, gamma-glutamyl transpeptidase, acid and base phosphatases, histidase, and tyrosinase, along with enhancing lipid peroxidation and histamine formation. Hyperkeratosis with dermal cell infiltration has been found.[20][21][22][23] Eczematoid contact dermatitis may result from chronic exposure.
Systemic toxic exposure to paraphenylenediamine affects multiple organ systems, including the integumentary, muscular, cardiorespiratory, and hepatorenal systems. The exact lethal dose has not yet been determined, but estimates range from 7 to 10 g.[24][25] The toxicity of paraphenylenediamine is mainly due to inhibition of cellular oxidation and subsequent corrosive properties.[1][4]
Benzoquinone diamine, an oxidative product of paraphenylenediamine also known as Bandrowski base, is known to cause significant tissue necrosis due to its highly toxic, allergenic, and mutagenic properties.[2][3][21] However, the United States Environmental Protection Agency has not classified paraphenylenediamine as a carcinogenic compound (US Environmental Protective Agency. P-Phenylenediamine). The median lethal dose (LD50) for oral ingestion is approximately 100 mg/kg in most animals, and the lowest published dose associated with toxicity is 71 mg/kg in humans (National Institute for Occupational Health and Safety. P-Phenylenediamine). However, there is a case report of a 44-year-old male who consumed 3 g of paraphenylenediamine (63 mg/kg) and ultimately died as a result of rhabdomyolysis and renal failure 3 days later.[26]
Systemic manifestations of paraphenylenediamine toxicity can be categorized as early manifestations and late manifestations. Early-stage clinical findings (4 to 6 hours) include oropharyngeal, cervicofacial, and angioneurotic edema, which may rapidly progress to airway occlusion and cause asphyxia and respiratory failure.[4][9] The underlying mechanism is largely believed to be due to precipitous inflammatory edema of the cricopharyngeal and laryngeal structures.[9]
Late-stage findings (>12 hours) include rhabdomyolysis and acute renal failure with associated clinical complications such as oliguria, anuria, renal tubular necrosis, arrhythmias, myocarditis, and acute hepatic injury.[4][19] Paraphenylenediamine is believed to induce rhabdomyolysis by triggering calcium ion leakage from the smooth endoplasmic reticulum, which causes rapid muscular contraction and muscle breakdown. The manifestation of acute renal failure in paraphenylenediamine toxicity is believed to be due to the combination of rhabdomyolysis, hypovolemia, and the direct toxin effect.[9] The pathogenesis of hepatic involvement is not well defined but is likely multifactorial. Cardiac manifestations have also been reported, including myocarditis, myocardial infarction, and arrhythmias, although the pathophysiology is poorly understood.[25][27][28]
Toxicokinetics
Literature evaluating the toxicokinetic properties of paraphenylenediamine in humans has mainly focused on transdermal exposure through the cosmetic hair dye industry. Although paraphenylenediamine is absorbed transdermally, its ability to cause a hypersensitivity reaction or dermatitis is not related to absorption but to its concentration, formulation, and exposure time. Studies have shown that dermal application of 1% and 2% paraphenylenediamine concentrations resulted in a peak serum concentration at 2 hours, but within 24 hours, paraphenylenediamine was undetectable in the serum.[29] This elimination is believed to be predominantly by renal excretion (90%).[30] An important clinical consideration for this is the potential for decreased elimination and prolonged toxicity in patients coming in with acute renal failure due to acute paraphenylenediamine toxicity, a well-documented complication. The metabolite identified in plasma and urine samples is predominantly N,N'-diacetylated-paraphenylenediamine. Fecal excretion was also minimally noted.[31] The half-life of elimination of paraphenylenediamine with dermal exposure is 7.8 hours (US Environmental Protective Agency. Provisional Peer-Reviewed Toxicity Values for p-Phenylenediamine). These studies are based on standardized commercial paraphenylenediamine concentrations no >2%, making it difficult to extrapolate to intoxications with higher concentrations.
The toxicokinetic effects of oral and intravenous dosing of paraphenylenediamine have only been studied in animal models. In studies with rats and mice, oral dosing showed almost complete absorption. Renal excretion was again noted as the predominant mode of elimination, with 90% of excretion occurring in the first 24 hours. The remainder of elimination was through feces with lower doses, which showed more feces excretion. This observation was theorized to be due to either the chemical being adsorbed to stomach contents or decreased enterohepatic recycling or alteration in the metabolite profile leading to increased excretion in bile. Biliary excretion was studied using intravenous exposure, which showed an inverse relation to the dose. This points to a hepatic metabolism route, suggesting that metabolism becomes saturated at higher doses. The distribution of paraphenylenediamine showed its presence in major tissues, including blood, kidneys, liver, muscles, skin, and adipose.[32] The half-life of elimination with oral absorption is unknown.
History and Physical
As the diagnosis of paraphenylenediamine toxicity requires a high index of suspicion due to its relatively rare occurrence in the Western community, thorough history-taking becomes crucial. As with other toxicologic histories, it is essential to determine the time, route, amount of product consumed, and potential for co-ingestion.[33] The specific product packaging can help identify the agent of concern and concentration used if available. In addition, psychiatric history, collateral history, and events leading up to clinical presentation are helpful details in cases due to intentional self-harm. Special care should be taken to identify the specific product of exposure due to varying concentrations of paraphenylenediamine used, although this may be difficult.[4]
As paraphenylenediamine toxicity does not have a specific pathognomonic physical examination finding, all systems should be carefully examined. Although nonspecific, the clinical findings commonly encountered were cervicofacial edema, upper airway edema, generalized muscle pain indicating rhabdomyolysis, and renal abnormalities such as oliguria, anuria, or chocolate-brown colored urine.[2][3][4] In patients with limited dermal toxicity, contact dermatitis at the site of use, typically the scalp or hairline, is present, and superinfection with cellulitis is possible.[20]
During a comprehensive physical examination, major clinical manifestations should be considered in a system-based manner as follows:
- Neurologic: Coma and convulsions [3]
- Cardiac: Arrhythmias including sinus tachycardia and bradycardia, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, and myocarditis [2]
- Respiratory: Dyspnea with underlying angioneurotic, cervicofacial, laryngeal, and oropharyngeal edema [34]
- Gastrointestinal: Dysphagia, abdominal pain, and acute hepatic injury [1][6]
- Renal: Chocolate brown urine, anuria, and oliguria [4][22]
- Musculoskeletal: Pain and rigidity of limbs, rhabdomyolysis [3]
- Integumentary: Pruritis, erythema, vesicular, or bullous dermatitis in areas of topical exposure, often involving the scalp, face, hands, and legs [20]
Evaluation
Evaluation of paraphenylenediamine toxicity may be largely nonspecific, but understanding its clinical features and expected course can help curate a work-up to limit morbidity and mortality.[35] Initial assessment should systemically evaluate for any airway compromise, signs of respiratory distress, or impending circulatory collapse. This evaluation can be achieved by a primary cardiorespiratory status evaluation using continuous hemodynamic monitoring, electrocardiography, chest x-ray, and venous blood gas. In addition, care should be taken to look for signs of suspected anaphylaxis or anaphylactic shock, as cases have rarely been reported.[36][37] Given that these patients are often approached with a broad differential diagnosis initially, evaluation should aim to exclude other potential pathology.
Although there is no specific laboratory or radiologic test to investigate paraphenylenediamine toxicity, a laboratory work-up should coincide with the clinical features of the presenting system involved and screening for further expected toxicity. Elevated creatine phosphokinase, lactate dehydrogenase, and hepatic transaminitis were found in most patients after oral ingestion.[6] Despite its limitations, serum creatinine remained the most common indicator for assessing renal dysfunction.[10] Urinalysis often showed myoglobin casts, likely alluding to evolving acute tubular necrosis. Additional nonspecific laboratory findings included leukocytosis, metabolic acidosis, hypocalcemia, and hyperphosphatemia.[14]
In cases of limited dermal exposure with no signs of systemic involvement, the work-up focuses on confirming the presence of a paraphenylenediamine allergy. The gold standard to confirm contact allergy with paraphenylenediamine is by cutaneous patch test using 1% paraphenylenediamine in petrolatum. The process entails applying a commercially prepared allergen onto a small skin patch for 48 hours. This method is followed by observing for any allergic reaction on day 2 and day 4. Alternative testing for patients with a high risk for severe reactions includes using paraphenylenediamine 0.3% for 2 days or paraphenylenediamine 1% for 1 hour. An in vitro lymphocyte activation test has also been described, but its use in clinical practice is currently limited.[20] These tests are often performed in outpatient settings.
Treatment / Management
There is no antidote or specific treatment for paraphenylenediamine toxicity. As a result, the mainstay of treatment consists of early recognition, airway management, correcting electrolyte and acid-base derangements, and aggressive supportive measures, particularly for significant exposures and ill individuals.[2][3][17]
Decontamination
Immediate removal of visible toxin remnants upon hospital arrival is crucial. The effectiveness of activated charcoal in paraphenylenediamine toxicity has not been well documented. Theoretically, its low molecular weight and nonpolar state make it a plausible option; however, its hydrophilic nature does not (PubChem. p-Phenylenediamine).[38] The use of gastric lavage in the initial stage of detoxification is controversial due to its potential to increase the risk of airway obstruction, particularly in the setting of significant airway edema and respiratory distress. In addition, the corrosive and caustic nature of paraphenylenediamine increases the theoretical risk of further caustic injury and esophageal perforation.[4][39](A1)
Airway Management
As respiratory failure and asphyxia were the most typical causes of death in paraphenylenediamine toxicity, prompt and aggressive airway management is crucial. Endotracheal intubation or tracheostomy with or without mechanical ventilation were commonly listed interventions.[3] However, as the significant underlying pathology for airway collapse is severe angioneurotic edema with laryngeal edema, endotracheal intubation is often deemed difficult, if not impossible.[40] Thus, tracheostomy was noted to be more commonly used. A systematic review found that 48% of cases underwent emergency tracheostomy.[4] The role of other airway interventions, such as fiberoptic intubation or cricothyroidotomy, is yet to be explored in the literature, but it appears at face value to be valuable adjuncts or alternative means of securing the airway.(A1)
Anaphylaxis Management
In the event of hypersensitivity or anaphylactic complications, corticosteroids and antihistamines were commonly integrated into the initial treatment regimen.[17] For patients with anaphylaxis, intramuscular epinephrine should also be administered and managed according to local anaphylaxis protocols.
Rhabdomyolysis and Acute Renal Injury Management
As a general consideration in these patients, it is critical to avoid dehydration and hypoxia as the presence of these conditions leads to worsening tissue breakdown, consequently leading to further renal injury.[40] Early administration of isotonic fluids (8 to 10 L/d) has been shown to limit the progression of acute renal injury due to rhabdomyolysis.[9][17][40] Although it remains unclear if paraphenylenediamine is amenable to dialysis, hemodialysis has been reported to aid renal recovery in cases of severe kidney failure.[10](B3)
Differential Diagnosis
The differential diagnoses of a patient presenting with paraphenylenediamine toxicity can be extensive due to its nonspecific clinical manifestations. Regardless, other causes with similar manifestations can be considered based on the hallmarks of the disease, which are rhabdomyolysis, cervicofacial angioedema, and acute kidney injury.[1] This list is not all-inclusive but may serve as a good starting point.[41][42] Differential diagnoses include the following:
- Substance abuse, such as synthetic cannabinoids, amphetamines, cocaine, and heroin
- Medication-induced nephrotoxicity, such as cyclosporine, vancomycin, and aminoglycosides
- Alcohol toxicity
- Occupational toxins, such as agrichemicals
- Heavy metal toxicity, such as calcium, lead, mercury, and uranium
- Snake bites, such as Viperidae and Elapidae
- Viral hepatitis
- Vascular ischemia
- Hypersensitivity and anaphylaxis
- Trauma and crush syndrome
- Malignant hyperthermia
- Metabolic myopathies
- Extreme physical activity-induced rhabdomyolysis
- Heat disorders, such as heat stroke and heat exhaustion
- Severe dehydration
Prognosis
The prognosis of paraphenylenediamine toxicity largely depends on the severity of exposure, timeliness of medical intervention, and the patient's overall health. Early recognition and prompt treatment significantly improve outcomes, with many patients recovering fully with appropriate care. Mild cases, characterized by localized skin reactions, generally resolve with symptomatic treatment and avoidance of further exposure.
However, severe cases involving systemic toxicity, such as rhabdomyolysis, renal failure, or anaphylaxis, can have a more guarded prognosis and may require intensive care. Renal recovery and improved clinical outcomes were observed with early clinical detection; prompt airway interventions; supportive medical management, such as fluids, steroids, antihistamines, and dialysis; and timely referral.[1][6][10][17][43]
Long-term complications, such as chronic kidney disease or persistent allergic sensitization, may impact the quality of life. Comprehensive follow-up care is crucial to monitor and manage any ongoing health issues, ultimately influencing the long-term prognosis.
The mortality rate of paraphenylenediamine toxicity has considerable variation in the current literature, with rates ranging from 0.03% to rates as high as 60%.[2][10][44] The most common causes of death were due to angioneurotic edema, respiratory failure, and fatal arrhythmias.[6][22] Several risk factors were linked to poor outcomes, which were late hospital presentation, no gastric lavage performed, tracheostomy or intubation requirement, neurologic involvement such as convulsions or low Glasgow Coma Scale score, established baseline renal failure, dialysis requirement, and intensive care unit admission.[14]
Complications
Paraphenylenediamine poisoning can cause life-threatening adverse effects affecting multiple organ systems, including neurologic, cardiac, respiratory, renal, and hepatic systems.[1] Although rare, cases of seizures and coma were reported.[4] Angioneurotic edema with subsequent airway compromise necessitating tracheostomy and hepatic and renal failure requiring hemodialysis were commonly documented.[22] Cardiac complications such as myocarditis, myocardial infarction, and fatal arrhythmias, including atrial fibrillation, ventricular tachycardia, and ventricular fibrillation, have been observed.[25][27][28] Severe allergic reactions, including anaphylaxis, can occur, posing immediate life-threatening risks. Chronic exposure may lead to sensitization and long-term dermatologic conditions.
Similar complications were noted in pediatric populations, such as the development of respiratory failure requiring tracheostomy and acute renal and hepatic failure requiring dialysis.[16][35] Prompt recognition and management of these complications are essential to mitigate adverse outcomes and ensure patient safety.
Consultations
Consultations for patients with paraphenylenediamine toxicity should involve a multidisciplinary approach to ensure comprehensive care. Toxicologists can provide specialized knowledge on managing chemical exposure and its systemic effects. Dermatologists may be consulted to address skin reactions and provide guidance on preventing further contact. Nephrologists might be necessary if there is evidence of renal impairment due to the toxin. In addition, allergists can offer insights into managing allergic reactions and preventing future episodes. Critical care specialists may be required for severe cases involving respiratory distress or multi-organ failure. Coordinating care among these specialists ensures that all aspects of paraphenylenediamine toxicity are addressed, enhancing patient outcomes and recovery.
Deterrence and Patient Education
With the global suicide rate increasing by 60% in the last 5 years, it is crucial to raise awareness of emerging trends.[9] The use of paraphenylenediamine as an agent of intentional self-harm has been increasing in the developing world, with concerning data suggesting that children, teenagers, and young adults are most affected.[17][16][18] Despite this, the dangers associated with paraphenylenediamine-containing agents are largely unknown to the general public. This issue is further complicated by the unregulated manufacturing of paraphenylenediamine in potentially dangerous concentrations in some parts of the world.[4]
Due to the potential high mortality linked to toxicity with this agent, raising public awareness and educating industry professionals become fundamental.[14] Educating patients about the potential risks of paraphenylenediamine, commonly found in hair dyes and certain occupational products, can significantly reduce exposure. Patients should be advised to read product labels carefully and seek out alternatives that do not contain paraphenylenediamine. In addition, healthcare professionals should inform patients about the early signs and symptoms of paraphenylenediamine toxicity, such as swelling, difficulty breathing, and dark urine, emphasizing the importance of seeking immediate medical attention if these occur. Effective communication and public awareness campaigns can further aid in reducing the incidence of paraphenylenediamine toxicity, ultimately safeguarding patient health. Further research is necessary to create effective deterrence strategies and public health awareness programs.
Pearls and Other Issues
Paraphenylenediamine toxicity is a serious condition that requires prompt and effective management. Clinical pearls offer key insights and practical tips for healthcare professionals to enhance their approach to diagnosing and treating paraphenylenediamine toxicity. By incorporating these guidelines, clinicians can improve patient outcomes and safety. Pertinent clinical pearls include the following:
- Early recognition: Identify early signs of toxicity, including angioedema, difficulty breathing, and dark-colored urine.
- History and exposure: Always obtain a detailed history of hair dye use or occupational exposure, as paraphenylenediamine is a common ingredient.
- Airway management: Be prepared for potential airway compromise due to severe angioedema; intubation may be necessary.
- Decontamination: Consider gastrointestinal decontamination if ingestion occurred within the last hour and the patient is stable.
- Symptomatic treatment: Administer antihistamines, corticosteroids, and epinephrine for allergic reactions and anaphylaxis.
- Dialysis: Be aware that severe cases with renal failure might require hemodialysis.
- Supportive care: Provide supportive care, including hydration and monitoring of renal function and electrolytes.
- Education: Educate patients on avoiding future exposure to paraphenylenediamine-containing products.
Enhancing Healthcare Team Outcomes
Improved clinical outcomes of patients presenting with paraphenylenediamine toxicity are significantly dictated by early diagnosis and appropriate clinical resuscitation. To ensure these patients receive optimal care with improved outcomes, a multidisciplinary collaborative methodology between healthcare professionals is imperative. The initial care of these patients entails that toxicologists, emergency medicine physicians, intensive care physicians, advanced practitioners, paramedics, nurses, pharmacists, and other healthcare team members have the crucial clinical knowledge and skills to diagnose and manage paraphenylenediamine toxicity. Further potential clinical complications may also necessitate the involvement of specialists in otolaryngology, nephrology, anesthesiology, cardiology, and laboratory medicine.
In addition, due to the often complex psychosocial elements involved in these cases, the role of case managers, social workers, and psychologists cannot be overstated. Ultimately, patients and caregivers should be counseled on the risks of paraphenylenediamine exposure to avoid recurrence while also receiving education on the care of complications, if present. Appropriate resources on suicide prevention and support should also be provided.
Strategizing evidence-based management plans while limiting adverse effects requires a well-planned approach. Critical decision-making must be sensitively guided by respecting patient autonomy and with informed consent. Patients presenting in critical conditions such as paraphenylenediamine toxicity warrant a well-functioning multidisciplinary team with effective team dynamics for better outcomes. Such an approach encompasses valuable interprofessional communication, seamless information exchange, and nonjudgmental information sharing during resuscitation. By recognizing that coordinating patient care from the emergency department to inpatient care and follow-up is the responsibility of all healthcare team members, better patient care and safety can be collectively achieved.
References
Asghar S, Mahbub S, Asghar S, Shahid S. Paraphenylenediamine (Hair Dye) Poisoning: A Prospective Study on the Clinical Outcome and Side Effects Profile. Cureus. 2022 Sep:14(9):e29133. doi: 10.7759/cureus.29133. Epub 2022 Sep 13 [PubMed PMID: 36258948]
Level 2 (mid-level) evidenceSayed AA, Abdelrahman AH, Sayed ZEA, Abdelhameid MA. Incidence and outcome of laryngeal edema and rhabdomyolysis after ingestion of black rock. International journal of emergency medicine. 2024 Jan 2:17(1):2. doi: 10.1186/s12245-023-00577-y. Epub 2024 Jan 2 [PubMed PMID: 38166608]
Omer Sultan M, Inam Khan M, Ali R, Farooque U, Hassan SA, Karimi S, Cheema O, Pillai B, Asghar F, Javed R. Paraphenylenediamine (Kala Pathar) Poisoning at the National Poison Control Center in Karachi: A Prospective Study. Cureus. 2020 May 29:12(5):e8352. doi: 10.7759/cureus.8352. Epub 2020 May 29 [PubMed PMID: 32617225]
Bhagavathula AS, Bandari DK, Khan M, Shehab A. A systematic review and meta-analysis of the prevalence and complications of paraphenylenediamine-containing hair dye poisoning in developing countries. Indian journal of pharmacology. 2019 Sep-Oct:51(5):302-315. doi: 10.4103/ijp.IJP_246_17. Epub 2019 Nov 26 [PubMed PMID: 31831919]
Level 1 (high-level) evidenceNohynek GJ, Antignac E, Re T, Toutain H. Safety assessment of personal care products/cosmetics and their ingredients. Toxicology and applied pharmacology. 2010 Mar 1:243(2):239-59. doi: 10.1016/j.taap.2009.12.001. Epub 2009 Dec 21 [PubMed PMID: 20005888]
Naqvi R, Akhtar F, Farooq U, Ashraf S, Rizvi SA. From diamonds to black stone; myth to reality: Acute kidney injury with paraphenylene diamine poisoning. Nephrology (Carlton, Vic.). 2015 Dec:20(12):887-91. doi: 10.1111/nep.12534. Epub [PubMed PMID: 26046254]
Pradhan R, Dandawate P, Vyas A, Padhye S, Biersack B, Schobert R, Ahmad A, Sarkar FH. From body art to anticancer activities: perspectives on medicinal properties of henna. Current drug targets. 2012 Dec:13(14):1777-98 [PubMed PMID: 23140289]
Level 3 (low-level) evidenceYazar K, Boman A, Lidén C. p-Phenylenediamine and other hair dye sensitizers in Spain. Contact dermatitis. 2012 Jan:66(1):27-32. doi: 10.1111/j.1600-0536.2011.01979.x. Epub 2011 Nov 15 [PubMed PMID: 22085034]
Sampathkumar K, Yesudas S. Hair dye poisoning and the developing world. Journal of emergencies, trauma, and shock. 2009 May:2(2):129-31. doi: 10.4103/0974-2700.50749. Epub [PubMed PMID: 19561974]
Shigidi M, Mohammed O, Ibrahim M, Taha E. Clinical presentation, treatment and outcome of paraphenylene-diamine induced acute kidney injury following hair dye poisoning: a cohort study. The Pan African medical journal. 2014:19():163. doi: 10.11604/pamj.2014.19.163.3740. Epub 2014 Oct 16 [PubMed PMID: 25810799]
Shalaby SA, Elmasry MK, Abd-Elrahman AE, Abd-Elkarim MA, Abd-Elhaleem ZA. Clinical profile of acute paraphenylenediamine intoxication in Egypt. Toxicology and industrial health. 2010 Mar:26(2):81-7. doi: 10.1177/0748233709360200. Epub 2010 Jan 26 [PubMed PMID: 20103579]
Patra AP, Shaha KK, Rayamane AP, Dash SK, Mohanty MK, Mohanty S. Paraphenylenediamine Containing Hair Dye: An Emerging Household Poisoning. The American journal of forensic medicine and pathology. 2015 Sep:36(3):167-71. doi: 10.1097/PAF.0000000000000165. Epub [PubMed PMID: 26056768]
Fatihi el M, Ramdani B, Benghanem MG, Hachim K, Zaid D. Rhabdomyolysis and acute renal failure secondary to toxic material abuse in morocco. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 1997 Apr-Jun:8(2):131-3 [PubMed PMID: 18417791]
Chrispal A, Begum A, Ramya I, Zachariah A. Hair dye poisoning--an emerging problem in the tropics: an experience from a tertiary care hospital in South India. Tropical doctor. 2010 Apr:40(2):100-3. doi: 10.1258/td.2010.090367. Epub [PubMed PMID: 20305106]
Ashraf W, Dawling S, Farrow LJ. Systemic paraphenylenediamine (PPD) poisoning: a case report and review. Human & experimental toxicology. 1994 Mar:13(3):167-70 [PubMed PMID: 7909678]
Level 3 (low-level) evidenceAbdelraheem MB, El-Tigani MA, Hassan EG, Ali MA, Mohamed IA, Nazik AE. Acute renal failure owing to paraphenylene diamine hair dye poisoning in Sudanese children. Annals of tropical paediatrics. 2009 Sep:29(3):191-6. doi: 10.1179/027249309X12467994693815. Epub [PubMed PMID: 19689860]
Elgassim M, Fadul KY, Abbas M, AlBakri F, Kamath R, Salem W. Paraphenylenediamine (PPD) Poisoning Mistaken for an Anaphylactic Reaction. Cureus. 2022 Feb:14(2):e22503. doi: 10.7759/cureus.22503. Epub 2022 Feb 22 [PubMed PMID: 35345732]
Güdeloğlu E, Erdur B. Retrospective evaluation of childhood paraphenylenediamine intoxication due to black henna. The Turkish journal of pediatrics. 2020:62(3):387-393. doi: 10.24953/turkjped.2020.03.005. Epub [PubMed PMID: 32558412]
Level 2 (mid-level) evidenceUmair SF, Amin I, Urrehman A. Hair Dye poisoning: "An early intervention". Pakistan journal of medical sciences. 2018 Jan-Feb:34(1):230-232. doi: 10.12669/pjms.341.14123. Epub [PubMed PMID: 29643913]
Mukkanna KS, Stone NM, Ingram JR. Para-phenylenediamine allergy: current perspectives on diagnosis and management. Journal of asthma and allergy. 2017:10():9-15. doi: 10.2147/JAA.S90265. Epub 2017 Jan 18 [PubMed PMID: 28176912]
Level 3 (low-level) evidenceMathur AK, Gupta BN, Singh S, Singh A, Narang S. Dermal toxicity of paraphenylenediamine. Biomedical and environmental sciences : BES. 1992 Dec:5(4):321-4 [PubMed PMID: 1489526]
Suliman SM, Fadlalla M, Nasr Mel M, Beliela MH, Fesseha S, Babiker M, Musa AR. Poisoning with hair-dye containing paraphenylene diamine: ten years experience. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 1995 Jul-Sep:6(3):286-9 [PubMed PMID: 18583736]
Mathur AK, Gupta BN, Narang S, Singh S, Mathur N, Singh A, Shukla LJ, Shanker R. Biochemical and histopathological changes following dermal exposure to paraphenylene diamine in guinea pigs. Journal of applied toxicology : JAT. 1990 Oct:10(5):383-6 [PubMed PMID: 2254591]
Chaudhary SC, Sawlani KK, Singh K. Paraphenylenediamine poisoning. Nigerian journal of clinical practice. 2013 Apr-Jun:16(2):258-9. doi: 10.4103/1119-3077.110138. Epub [PubMed PMID: 23563473]
Jain PK, Sharma AK, Agarwal N, Jain PK, Sengar NS, Agarwal N, Siddiqui MZ, Pawal P, Singh AK, Gaba RD. A prospective clinical study of myocarditis in cases of acute ingestion of paraphenylene diamine (hair dye) poisoning in northern India. The Journal of the Association of Physicians of India. 2013 Sep:61(9):633-6, 644 [PubMed PMID: 24772701]
Level 3 (low-level) evidenceSaito K, Murai T, Yabe K, Hara M, Watanabe H, Hurukawa T. [Rhabdomyolysis due to paraphenylenediamine (hair dye)--report of an autopsy case]. Nihon hoigaku zasshi = The Japanese journal of legal medicine. 1990 Dec:44(5-6):469-74 [PubMed PMID: 2079768]
Level 3 (low-level) evidenceBrahmi N, Kouraichi N, Blel Y, Mourali S, Thabet H, Mechmeche R, Amamou M. Acute myocarditis and myocardial infarction induced by Paraphenylenediamine poisoning. Interest of angiocoronarography. International journal of cardiology. 2006 Nov 18:113(3):E93-5 [PubMed PMID: 16890306]
Singh N, Jatav OP, Gupta RK, Tailor MK. Myocardial damage in hair dye poisoning--an uncommon presentation. The Journal of the Association of Physicians of India. 2008 Jun:56():463-4 [PubMed PMID: 18822628]
Pot LM, Scheitza SM, Coenraads PJ, Blömeke B. Penetration and haptenation of p-phenylenediamine. Contact dermatitis. 2013 Apr:68(4):193-207. doi: 10.1111/cod.12032. Epub [PubMed PMID: 23510340]
Hueber-Becker F, Nohynek GJ, Meuling WJ, Benech-Kieffer F, Toutain H. Human systemic exposure to a [14C]-para-phenylenediamine-containing oxidative hair dye and correlation with in vitro percutaneous absorption in human or pig skin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2004 Aug:42(8):1227-36 [PubMed PMID: 15207372]
Nohynek GJ, Skare JA, Meuling WJA, Wehmeyer KR, de Bie ATHJ, Vaes WHJ, Dufour EK, Fautz R, Steiling W, Bramante M, Toutain H. Human systemic exposure to [¹⁴C]-paraphenylenediamine-containing oxidative hair dyes: Absorption, kinetics, metabolism, excretion and safety assessment. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2015 Jul:81():71-80. doi: 10.1016/j.fct.2015.04.003. Epub 2015 Apr 3 [PubMed PMID: 25846501]
Ioannou YM, Matthews HB. p-Phenylenediamine dihydrochloride: comparative disposition in male and female rats and mice. Journal of toxicology and environmental health. 1985:16(2):299-313 [PubMed PMID: 4078935]
Level 2 (mid-level) evidenceThompson TM, Theobald J, Lu J, Erickson TB. The general approach to the poisoned patient. Disease-a-month : DM. 2014 Nov:60(11):509-24. doi: 10.1016/j.disamonth.2014.10.002. Epub 2014 Nov 7 [PubMed PMID: 25454682]
Kallel H, Chelly H, Dammak H, Bahloul M, Ksibi H, Hamida CB, Chaari A, Rekik N, De Broe ME, Bouaziz M. Clinical manifestations of systemic paraphenylene diamine intoxication. Journal of nephrology. 2005 May-Jun:18(3):308-11 [PubMed PMID: 16013020]
Sir Hashim M, Hamza YO, Yahia B, Khogali FM, Sulieman GI. Poisoning from henna dye and para-phenylenediamine mixtures in children in Khartoum. Annals of tropical paediatrics. 1992:12(1):3-6 [PubMed PMID: 1376583]
Belton AL, Chira T. Fatal anaphylactic reaction to hair dye. The American journal of forensic medicine and pathology. 1997 Sep:18(3):290-2 [PubMed PMID: 9290878]
Goldberg BJ, Herman FF, Hirata I. Systemic anaphylaxis due to an oxidation product of p-phenylenediamine in a hair dye. Annals of allergy. 1987 Mar:58(3):205-8 [PubMed PMID: 3826772]
Silberman J, Galuska MA, Taylor A. Activated Charcoal. StatPearls. 2024 Jan:(): [PubMed PMID: 29493919]
Lanphear WF. Gastric lavage. The Journal of emergency medicine. 1986:4(1):43-7 [PubMed PMID: 3734388]
Anuradha S, Arora S, Mehrotra S, Arora A, Kar P. Acute renal failure following para-phenylenediamine (PPD) poisoning: a case report and review. Renal failure. 2004 May:26(3):329-32 [PubMed PMID: 15354985]
Level 3 (low-level) evidencePetejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Critical care (London, England). 2014 May 28:18(3):224. doi: 10.1186/cc13897. Epub 2014 May 28 [PubMed PMID: 25043142]
Petejova N, Martinek A, Zadrazil J, Teplan V. Acute toxic kidney injury. Renal failure. 2019 Nov:41(1):576-594. doi: 10.1080/0886022X.2019.1628780. Epub [PubMed PMID: 31237170]
Gowda NR, Delio J, Elshikh A, Khosla R. Hair-Dye-Related Accidental Poisoning and Death. Cureus. 2021 Apr 21:13(4):e14607. doi: 10.7759/cureus.14607. Epub 2021 Apr 21 [PubMed PMID: 34079664]
Gude D, Bansal DP, Ambegaonkar R, Prajapati J. Paraphenylenediamine: Blackening more than just hair. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2012 Jun:17(6):584-6 [PubMed PMID: 23626641]